NCT05692635 2026-03-20
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
Wake Forest University Health Sciences
Phase 2 Recruiting
Clinical Trials
11 trialsNCT03270059 2026-02-27
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
OHSU Knight Cancer Institute
Phase 2 Recruiting
NCT04474353 2025-12-26
Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma
Stanford University
Phase 1 Completed
NCT03565367 2023-12-21
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors
Stanford University
Phase 1 Completed
NCT04264143 2023-12-18
CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas
Columbia University
Phase 1 Completed
NCT00659126 2023-09-07
Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00978562 2022-08-03
DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Completed
NCT03154996 2022-07-05
Chronic Convection Enhanced Delivery of Topotecan
Columbia University
Phase 1 Completed
NCT00103038 2022-06-09
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
OHSU Knight Cancer Institute
Phase NA Completed
NCT02590497 2018-01-31
Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery
Ohio State University Comprehensive Cancer Center
Phase NA Withdrawn
NCT00660543 2017-05-16
MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy
OHSU Knight Cancer Institute
Phase NA Completed